How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,901 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1681. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Full Text available with Trip Pro

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection.We (...) report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod (n = 22) or vehicle cream (n = 14) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hours for 4 or 8 days). RNA was amplified and hybridized to 17.5 K cDNA arrays. All treatment schedules similarly affected the transcriptional profile of BCC; however, the q12 x 4 days regimen, associated

2007 Genome biology Controlled trial quality: uncertain

1682. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Full Text available with Trip Pro

Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. To determine the efficacy and safety of imiquimod in combination with meglumine antimoniate in treating cutaneous leishmaniasis.Prospective, randomized, assessor-blind, parallel-design, placebo-controlled trial.Two primary care health clinics.One hundred nineteen patients (59 patients in the imiquimod group and 60 in the placebo group) were included (...) in the study.Patients were randomly assigned to receive a combined 4-week course of imiquimod or placebo with meglumine antimoniate treatment (20 mg/kg of pentavalent antimony daily for 2 weeks) in an endemic area of Leishmania tropica.The primary end point was clinical cure, defined as more than 75% reduction in the size of lesions compared with baseline at week 8.At the end of the 4-week treatment period, clinical cure was similar in both groups (11 patients [18.6%] in the imiquimod-treated group vs 18 patients

2006 Archives of Dermatology Controlled trial quality: predicted high

1683. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. (Abstract)

Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. It is timely to compare the efficacy and tolerability of 2 actinic keratosis (AK) therapies--5% 5-fluorouracil (5-FU) cream and imiquimod cream. Thirty-six patients with 4 or more AKs were randomly assigned to receive 5% 5-FU cream twice daily for 2 to 4 weeks or 5% imiquimod cream twice weekly for 16 weeks. Five percent 5-FU was more effective than imiquimod in exposing (...) what were presumed to be subclinical AKs, reducing the final AK count (total AK count declined during the 24-week study by 94% vs. 66%, P < .05), achieving complete clearance (incidence of 84% vs. 24% by week 24, P < .01), and achieving clearance rapidly. Tolerability was similar except for erythema, which was initially significantly higher with 5-FU than imiquimod but resolved rapidly and was significantly lower than imiquimod by week 16. Five percent 5-FU remains the gold standard field therapy

2007 Journal of drugs in dermatology : JDD Controlled trial quality: uncertain

1684. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Full Text available with Trip Pro

Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Cutaneous leishmaniasis is a serious public health problem in the developing world. The main therapeutic agent--pentavalent antimony, developed >50 years ago--is expensive, often accompanied by severe adverse effects, and complicated by the emergence of drug resistance. Better therapies are urgently needed. In the present pilot study, we compared the use of imiquimod, an immunomodulatory (...) molecule, to the use of meglumine antimoniate alone and in combination for the initial treatment of cutaneous leishmaniasis.Patients with newly diagnosed cutaneous leishmaniasis were enrolled from a single referral center in Lima, Peru, from August 2005 through October 2005. Patients were randomly assigned to 1 of 3 treatment groups and received either imiquimod 7.5% cream administered topically every other day for 20 days, intravenous meglumine antimoniate administered at a dosage of 20 mg/kg per day

2007 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Controlled trial quality: uncertain

1685. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. (Abstract)

Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Imiquimod has been investigated as a safe and effective therapeutic option for the treatment of actinic keratosis (AK).To evaluate imiquimod vs. vehicle applied three times a week for 4 weeks in one or two courses of treatment for AK on the face or balding scalp.Patients diagnosed with AK (...) were enrolled in this multicentre, vehicle-controlled, double-blind study conducted in Europe. Twenty study centres enrolled a total of 259 patients in this study. Patients applied the study drug for 4 weeks, entered a 4-week rest period and if they did not have complete clearance, they then entered a second course of treatment.Patients in the imiquimod group had an overall complete clearance rate of 55.0% (71/129) vs. a rate of 2.3% (3/130) for the vehicle group. There was a high rate of agreement

2007 The British journal of dermatology Controlled trial quality: uncertain

1686. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. (Abstract)

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. The present study was planned to evaluate the efficacy and tolerability of topical treatment with imiquimod in nodular basal cell carcinoma (nBCC).One hundred two patients were randomized to receive thrice-weekly topical imiquimod for either 8 or 12 weeks. Twelve patients dropped out. A total of 90

2007 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

1687. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. (Abstract)

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. A shorter dosing regimen of imiquimod for the treatment of actinic keratosis may be effective, with long-term clinical benefits.Imiquimod in one or two shorter courses of treatment was evaluated.Patients with actinic keratosis lesions on the head applied imiquimod or vehicle cream 3x/wk for 4 weeks (course 1). Patients (...) with remaining lesions received another course of treatment. Complete and partial clearance rates were evaluated after course 1, after course 2 (overall), and 1 year later.Complete clearance rates were 26.8% (course 1) and 53.7% (overall). Partial clearance rates were 36.6% (course 1) and 61.0% (overall). One-year follow-up recurrence rates were 39% (imiquimod) and 57% (vehicle).Blinded investigators may have been biased toward patients treated with imiquimod identified by treatment site reactions.Imiquimod

2007 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

1688. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. (Abstract)

Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. We conducted a double-blind, placebo-controlled, randomized trial to evaluate the preliminary efficacy and safety of imiquimod 5% cream treatment for cutaneous squamous cell carcinoma (SCC) in situ.In all, 31 patients with biopsy-proven cutaneous SCC in situ were randomly assigned to placebo (vehicle) (n = 16) or imiquimod 5% cream (n = 15) daily (...) for 16 weeks. Patients were assessed at week 28 for the primary end point, resolution of cutaneous SCC in situ.Of the 31 patients enrolled, 3 dropped out. Intention-to-treat analysis revealed 11 of the 15 patients (73%) in the imiquimod group achieved resolution of cutaneous SCC in situ, with no relapse during the 9-month follow-up period; none in the placebo group achieved resolution (P < .001). Imiquimod 5% cream was generally well tolerated and there were no serious adverse events.Topical

2006 Journal of the American Academy of Dermatology Controlled trial quality: predicted high

1689. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. (Abstract)

An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Our objective was to determine the optimal duration of treatment with imiquimod for external genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts for a median of 3-6 months and prior alternative treatments in 73% were evaluated for total clearance rates. There was no statistically significant difference (...) in complete clearance rates after 16-week follow-up across treatment groups: four weeks (40.0%), eight weeks (48.4%), 12 weeks (39.3%) and 16 weeks (51.6%). Imiquimod was well tolerated, and in those treated for four weeks there was a lower incidence of local skin reactions such as erythema and erosion, and no incidences of pain. These preliminary results suggest that a four-week treatment course of imiquimod applied thrice weekly for women with external genital warts may provide a reasonable approach

2006 International journal of STD & AIDS Controlled trial quality: uncertain

1690. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. (Abstract)

Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. Cryotherapy is the standard of care for clinically apparent (target) actinic keratoses (AKs). Topical imiquimod may reduce initially inapparent or subclinical AKs.We evaluated the potential of topical imiquimod to decrease subclinical AKs after cryotherapy of target AKs.A randomized trial of imiquimod or vehicle twice weekly for 8 weeks following 3- to 5-second cryotherapy of target AKs within a 50 cm(2) field at the face (...) or scalp was conducted. Efficacy outcomes included clearance of target, subclinical, and total AKs and proportions clear of AKs. Subjects with residual AKs were offered cryotherapy and open-label imiquimod twice weekly for 8 weeks.Sixty-three subjects completed the randomized phase. At 12 weeks, target AK clearance was similar for imiquimod and vehicle (79% vs 76%), but fewer total AKs were noted for imiquimod (78 vs 116). This was due to a progressive reduction in subclinical AKs with imiquimod

2007 Journal of cutaneous medicine and surgery Controlled trial quality: uncertain

1691. Combination Therapy with Imiquimod, 5-Fluorouracil, and Tazarotene in the Treatment of Extensive Radiation-Induced Bowen's Disease of the Hands. (Abstract)

Combination Therapy with Imiquimod, 5-Fluorouracil, and Tazarotene in the Treatment of Extensive Radiation-Induced Bowen's Disease of the Hands. 19732103 2010 07 06 2018 12 01 1524-4725 36 5 2010 May Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Combination therapy with imiquimod, 5-fluorouracil, and tazarotene in the treatment of extensive radiation-induced Bowen's disease of the hands. 694-700 10.1111/j.1524-4725.2009.01325.x (...) Modi Gunjan G Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA. Jacobs Aleda A AA Orengo Ida F IF McClung Amy A Rosen Ted T eng Case Reports Journal Article 2009 09 01 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents 0 Dermatologic Agents 0 Nicotinic Acids 81BDR9Y8PS tazarotene P1QW714R7M Imiquimod U3P01618RT Fluorouracil IM Aminoquinolines administration & dosage therapeutic use Antineoplastic Agents administration & dosage

2009 Dermatologic Surgery

1692. What Lies Beneath? A Lesson for the Clinician. Intraoperative Frozen Section Appearance of Persistent Basal Cell Carcinoma after Apparent Cure with Imiquimod 5% Cream. Full Text available with Trip Pro

What Lies Beneath? A Lesson for the Clinician. Intraoperative Frozen Section Appearance of Persistent Basal Cell Carcinoma after Apparent Cure with Imiquimod 5% Cream. 19691665 2009 12 11 2018 12 01 1524-4725 35 11 2009 Nov Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg What lies beneath? A lesson for the clinician. Intraoperative frozen section appearance of persistent basal cell carcinoma after apparent cure with imiquimod 5 (...) % cream. 1831-4 10.1111/j.1524-4725.2009.01300.x Sukal Sean A SA Laser and Skin Surgery Center of New York, New York, New York 10016, USA. Mahlberg Matthew J MJ Brightman Lori L Daniel David R DR Mintzis Medwin M MM Geronemus Roy G RG eng Case Reports Journal Article 2009 08 18 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents 0 Ointments P1QW714R7M Imiquimod IM Administration, Topical Adult Aminoquinolines administration & dosage Antineoplastic Agents therapeutic

2009 Dermatologic Surgery

1693. Recurrence of Lentigo Maligna and Development of Invasive Melanoma after Treatment of Lentigo Maligna with Imiquimod. (Abstract)

Recurrence of Lentigo Maligna and Development of Invasive Melanoma after Treatment of Lentigo Maligna with Imiquimod. 19438661 2009 08 31 2018 12 01 1524-4725 35 8 2009 Aug Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. 1286-9 10.1111/j.1524-4725.2009.01227.x Woodmansee Courtney S CS Department of Medicine (...) , Division of Dermatology, University of Louisville, Louisville, KY, USA. McCall Michael W MW eng Case Reports Journal Article 2009 05 12 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Aged Aminoquinolines adverse effects Antineoplastic Agents adverse effects Facial Neoplasms drug therapy pathology Humans Hutchinson's Melanotic Freckle drug therapy pathology Imiquimod Male Neoplasm Invasiveness Neoplasm Recurrence, Local Skin Neoplasms drug

2009 Dermatologic Surgery

1694. Topical application of imiquimod induces alterations in peripheral blood lymphocytes in healthy individuals*. (Abstract)

Topical application of imiquimod induces alterations in peripheral blood lymphocytes in healthy individuals*. The aim of this study was to determine whether imiquimod, a Toll-like receptor-7/8 agonist, in addition to its well-known topical action on the cutaneous immune response, might also induce alterations in the peripheral blood lymphocytes. A 62.5 mg quantity of imiquimod (5% cream) was applied topically under occlusion once daily every second day for 3 weeks to the skin of 10 healthy (...) volunteers, age range 30-57 years. Ten sex- and age-matched healthy controls applied corresponding quantities of the vehicle under occlusion. Before, and one and 3 weeks after the start of treatment, peripheral blood lymphocyte subpopulations were measured by flow cytometry. Statistically significant alterations in the percentage or absolute numbers of peripheral blood lymphocyte subpopulations were found in the imiquimod-treated group compared with the control group. These alterations indicate

2009 Acta Dermato-Venereologica

1695. The Use of Imiquimod to Minimize the Surgical Defect When Excising Invasive Malignant Melanoma Surrounded by Extensive Melanoma In Situ, Lentiginous Type. (Abstract)

The Use of Imiquimod to Minimize the Surgical Defect When Excising Invasive Malignant Melanoma Surrounded by Extensive Melanoma In Situ, Lentiginous Type. 19389091 2009 06 09 2018 12 01 1524-4725 35 5 2009 May Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg The use of imiquimod to minimize the surgical defect when excising invasive malignant melanoma surrounded by extensive melanoma in situ, lentiginous type. 868-74 10.1111/j.1524 (...) -4725.2009.01146.x Missall Tricia A TA Department of Dermatology, Saint Louis University Cancer Center, Saint Louis University School of Medicine, Missouri, 63104, USA. Fosko Scott W SW eng Case Reports Journal Article 2009 03 30 United States Dermatol Surg 9504371 1076-0512 0 Adjuvants, Immunologic 0 Aminoquinolines P1QW714R7M Imiquimod IM Adjuvants, Immunologic therapeutic use Aged, 80 and over Aminoquinolines therapeutic use Cheek Female Follow-Up Studies Humans Imiquimod Male Melanoma pathology surgery

2009 Dermatologic Surgery

1696. Definitive Surgical Treatment of 24 Skin Cancers Not Cured by Prior Imiquimod Therapy: A Case Series. (Abstract)

Definitive Surgical Treatment of 24 Skin Cancers Not Cured by Prior Imiquimod Therapy: A Case Series. 18554288 2009 04 07 2018 12 01 1524-4725 34 9 2008 Sep Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series. 1258-63 10.1111/j.1524-4725.2008.34271.x Murphy Michael E ME The Indiana Skin Cancer Center, Indianapolis, IN 46143, USA (...) . murphymd1@gmail.com Brodland David G DG Zitelli John A JA eng Case Reports Journal Article 2008 06 12 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Aged Aminoquinolines therapeutic use Antineoplastic Agents therapeutic use Carcinoma, Basal Cell drug therapy surgery Carcinoma, Squamous Cell drug therapy surgery Female Humans Imiquimod Male Melanoma drug therapy surgery Middle Aged Mohs Surgery Skin Neoplasms drug therapy surgery Treatment

2008 Dermatologic Surgery

1697. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. (Abstract)

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Patients with metastatic skin disease in malignant melanoma are difficult to treat, with unresectable lesions proving the biggest challenge. We have recently published data showing a significant clinical response in patients with multiple in-transit melanoma metastases treated with a combination of topical imiquimod and intralesional interleukin (...) showed an increase in the ability of cells to produce interferon (IFN)-gamma over the treatment course, with an initial rise in the IFN-gamma/IL-5 ratio in five of six patients.The results of this study provide evidence that, in the majority of patients with in-transit metastases of melanoma, therapy with a combination of topical imiquimod and intralesional IL-2 induces a systemic immunological effect by reversing some of changes noted in patients with malignant disease.

2008 British Journal of Dermatology

1698. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. (Abstract)

Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. Although the effectiveness of daily dosing regimens of 5% imiquimod cream for the treatment of superficial basal cell carcinomas (sBCC) has been documented by recent studies, concerns about long-term outcome remain. The majority of efficacy data is based on clinical clearance and limited histological examination (...) which may not identify tumour presence at the periphery.To assess the efficacy of 5% imiquimod cream for sBCC using detailed histological assessment 1 year after completion of treatment.Nine individuals with biopsy-proven sBCC treated with 5% imiquimod cream 1 year previously and who remained clinically clear were recruited. Paraffin-embedded excision specimens from the original tumour site were extensively examined by a dermatopathologist. Examination and analysis of frozen sections of the original

2008 Journal of Dermatological Treatment

1699. Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis. (Abstract)

Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis. To investigate the efficacy of imiquimod on endometriosis.Randomized, placebo-controlled, single-blind, experimental study.Experimental surgery laboratory at a university in Turkey.Thirty Wistar female rats.After the peritoneal implantation of endometrial tissue, rats were randomized to two equal intervention groups: [1] the control group and [2] the imiquimod group. Six weeks later, after implant volume (...) was measured (volume 1) by performing a second laparotomy, imiquimod (10 mg intraperitoneally per rat, 2 times per wk) was administered to the imiquimod group, and saline solution (0.1 mL SC, once per wk), to the control group, for 8 weeks. At the end of the treatment, a third laparotomy was performed to remeasure implant volumes (volume 2), and implants were totally excised for histopathologic examination.To compare volume 1 and volume 2 within the groups, as well as stromal and glandular tissues between

2007 Fertility and Sterility

1700. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Full Text available with Trip Pro

Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. The pathogenesis of vitiligo was examined for clues to the pigmentary changes that may occur after treatment with topical imiquimod. The literature varies on the pigmentary changes induced by topical use of imiquimod. The US Food and Drugs Administration lists 68 reports of pigmentary changes out of a total of 1257 reports related to imiquimod lodged from 1997 to 2003. Some studies describe vitiligo (...) -like hypopigmentation associated with imiquimod treatment of genital warts (as with the patient described in this report), molluscum contagiosum, basal cell carcinoma, extramammary Paget's disease and murine melanoma. Other studies report hyperpigmentation associated with imiquimod. The possible mechanisms of hypopigmentation associated with imiquimod treatment are discussed, including antibodies found in sera of patients with vitiligo to nonpigment cell antigens, cytoplasmic pigment cell antigens

2007 Clinical & Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>